Project Grant R44DK096706

Persista Bio Inc. received a $3.28 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) awarded on September 8, 2025. The grant funds advanced preclinical development of the O2LINE System, a safe, anti-fibrotic, oxygenated cell encapsulation device designed to enable Type 1 Diabetes (T1D) cell replacement therapy without the need for immunosuppression....

Federal Grant Award Summary Persista Bio Inc. received $287,250 in Project Grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and manufacture clinical-grade cell capsules for the O2LINE implant system, an advanced oxygenated cell encapsulation technology for Type 1 Diabetes (T1D) treatment. The award, granted on September 11, 2025, with completion...

Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded University of Notre Dame DU Lac a $745,249 Project Grant on September 1, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a once-weekly, glucose-responsive insulin formulation. The research addresses a critical therapeutic need in diabetes management by creating an insulin product that dynamically adjusts its bioavailability...

Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Indiana University Indianapolis a Project Grant totaling $811,217 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on February 18, 2026, with a completion date of January 31, 2031. This research grant supports a multi-principal investigator (MPI) investigation into the signaling mechanisms of ultra-stable and glucose-responsive...

Federal Project Grant Award Summary SNC Therapeutics, Inc. received a $700,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the development of tolerogenic nanotherapy to delay Type 1 Diabetes (T1D). The award, effective July 25, 2025 through July 24, 2026, supports research on rapamycin-loaded polymersomes (RPS)—vesicular nanoparticles designed...

Grant Award Summary Biotherapeutics, Inc. received a $719,250 Project Grant award effective July 1, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This Small Business Innovation Research (SBIR) Phase I grant supports the development of next-generation oral, once-daily precision medicine therapeutic candidates for the treatment of prediabetes and Type 2 Diabetes...

Federal Grant Award Summary The Jaeb Center for Health Research Foundation, Inc. received a $2.34 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 3, 2025, with completion scheduled for August 31, 2028. The project, titled "Care Partner-Assisted Implementation of Patch Hybrid Closed Loop Insulin Delivery for Older Adults...

The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...

This National Science Foundation (NSF) Division of Computer and Network Systems Project Grant award totaling $839,998 to Michigan State University supports the development of a novel wireless optoelectronic implant system for closed-loop control of bi-hormone (insulin and glucagon) secretion from genetically modified islet organoids. The goal is to create an implantable, wireless, and battery-free device that can precisely regulate hormone levels to manage type 1 diabetes. The project involves...

The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded a $450,000 Project Grant to the Texas A&M Engineering Experiment Station (Tees) to develop an injectable, grain-of-rice size glucose biosensor for continuous blood sugar monitoring. The key products or services to be provided under this 3-year grant include: Developing an injectable glucose biosensor comprised of a self-cleaning membrane and a near-infrared fluorescence...